In der Ausgabe 11 von Systembiologie, dem Magazin für systembiologische Forschung in Deutschland, findet sich, neben vielen anderen spannenden Berichten ein vierseitiges Unternehmenspotrait der Alacris. Wir freuen uns sehr darüber und wollen Sie auf den Bericht ab Seite 70 hinweisen.
Read MoreWissenschaftler von Alacris präsentieren eine elektrophoresefreie Methode zur Beurteilung der Fragmentierungsaktivität von Tn5-Transposomen in ‘tagmentation’-Reaktionen. Der Assay ermöglicht es, die relative Effizienz von Tn5-transposome-assemblies unter verschiedenen experimentellen Bedingungen quantitativ zu bestimmen und Chargen-Unterschiede in Transposomen für die Erstellung von NGS-Bibliotheken zu normalisieren. Der Test ist qPCR-basiert und daher extrem robust, schnell, kosten- und zeiteffizient. Lesen […]
Read MoreNew biomarkers for bowel cancer treatment Scientists can predict in the lab whether a drug will be effective for individual colorectal tumors Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one of Europe’s largest […]
Read MoreThe quality management of Alacris Theranostics GmbH has been certified by TÜV Süd according to ISO 9001:2015. Alacris therefore fulfills the requirements for a quality management system according to the latest revision of ISO 9001. Alacris focuses on personalized medicine and requires its own state-of-the-art next-generation sequencing lab with an efficient sequencing and data analysis […]
Read MoreProf. Dr. Hans Lehrach, Gründer der Alacris Theranostics GmbH, spricht in der aktuellen Ausgabe der “Diagnostik im Gespräch” über die Notwendigkeit und Möglichkeiten der personalisierten Medizin. Jeder Mensch verfügt über ein einzigartiges genetisches Profil, verschiedene Zustände des Immunsystems, Vorerkrankungen und verschiedenes Verhalten. Dies hat selbstverständlich Auswirkungen auf die Ableitung der optimalen Therapie für jeden einzelnen […]
Read MoreIn the current issue 6/2016 of the German Life Sciences-Magazine |transkript the CEO of Alacris Theranostics GmbH speaks about virtual cancer models and his role as project coorindator in the European consortium CanPathPro. CanPathPro. CanPathPro brings together classic cancer research with omics data and systems biology tools for new approaches in the fight againts cancer. […]
Read MoreDer Stifterverband für die Deutsche Wissenschaft e.V has honored Alacris’ innovations with his seal of approval. Since 2014 the Stifterverband honors research companies for the particular responsibility they assume for state and society, with this seal of approval, and after answering a detailed questionnaire submitted by the Stifterverband, it is official: Alacris is “Innovative through […]
Read MoreAn international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems biology platform for predictive modelling of cancer signalling. The EU Horizon 2020 funded project, co-ordinated by Alacris Theranostics GmbH, Berlin, will run for 5 years with a budget of almost 11 million euros. The European Research […]
Read MoreThe online news organization Genome Web informs that the European Commission has awarded a group of researchers and companies €2.9 million ($3.3 million) to develop new technologies for high-throughput protein sequencing and single-molecule DNA and RNA sequencing. The project, called “Protein sequencing using optical single-molecule real-time detection” and dubbed PROSEQO for short, commenced March 2016 […]
Read MoreThe 2016 Biotechnology Awards showcase the very best talent, dedication and discoveries from firms working in the field of healthcare. Alacris’ revolutionary systems medicine modelling approach (ModCell™), to better match patients to therapies (‘virtual patients’) and therapies to patients (‘virtual clinical trials’) and Alacris’ unique oncogenomic pipeline was selected by the jury for “Best for […]
Read More